Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 3/20 | 0.40 |
| ▸ | RAB9A | P51151 | 3/20 | 0.40 |
| ▸ | GRIN2B | Q13224 | 7/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | DRD4 | P21917 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL995296 | 1.00 | NPC1 (0.40) | NPC1RAB9AGRIN2BALDH1A1DRD4 | |
| SCHEMBL3556036 | 0.83 | GRIN2B (0.36) | GRIN2B | |
| SCHEMBL2817469 | 0.83 | GRIN2B (0.36) | GRIN2B | |
| SCHEMBL2819757 | 0.78 | — | — | |
| SCHEMBL3547375 | 0.78 | — | — | |
| SCHEMBL3550557 | 0.76 | GRIN2B (0.38) | GRIN2B | |
| SCHEMBL2818626 | 0.76 | GRIN2B (0.38) | GRIN2B | |
| SCHEMBL995504 | 0.75 | ALDH1A1 (0.35) | GRIN2BALDH1A1POLBKMT2A | |
| SCHEMBL995503 | 0.75 | ALDH1A1 (0.35) | GRIN2BALDH1A1POLBKMT2A | |
| SCHEMBL2818160 | 0.75 | HSD11B1 (0.40) | GRIN2BALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8178554-B2 | Heterocyclic compounds, their preparation and their use as medicaments, in particular as anti-bacterial agents | ALLERGAN PHARMACEUTICALS INTERNATIONAL LIMITED (IE) | 2012-05-15 | — | — | US | disclosed |
| US-8148540-B2 | Heterocyclic compounds, their preparation and their use as medicaments, in particular as anti-bacterial agents | ASTRAZENECA (SE) | 2012-04-03 | — | — | US | disclosed |
| US-20110245254-A1 | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF BETA-LACTAMASES | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2011-10-06 | — | — | US | disclosed |
| US-20110213147-A1 | New heterocyclic compounds, their preparation and their use as medicaments, in particular as anti-bacterial agents | AVENTIS PHARMA S.A. | 2011-09-01 | — | — | US | disclosed |
| US-20110021772-A1 | New heterocyclic compounds, their preparation and their use as medicaments, in particular as anti-bacterial agents | AVENTIS PHARMA S.A. | 2011-01-27 | — | — | US | disclosed |
| US-7732610-B2 | Heterocyclic compounds, their preparation and their use as medicaments, in particular as anti-bacterial agents | AVENTIS PHARMA S.A. (FR) | 2010-06-08 | — | — | US | disclosed |
| US-20100048528-A1 | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF BETA-LACTAMASES | NOVEXEL (FR) | 2010-02-25 | — | — | US | disclosed |
| US-7638529-B2 | anti-bacterial agents; staphylococci; coliform bacteria; 7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide; bridged bicyclic ureas or carbamates having bridgehead nitrogen | AVENTIS PHARMA S.A. (FR) | 2009-12-29 | — | — | US | disclosed |
| US-7612087-B2 | Therapy for bacteria infections | NOVEXEL (FR) | 2009-11-03 | — | — | US | disclosed |
| US-20090215747-A1 | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF BETA-LACTAMASES | AVENTIS PHARMA S.A. (FR) | 2009-08-27 | — | — | US | disclosed |
| US-20070299108-A1 | New heterocyclic compounds, their preparation and their use as medicaments, in particular as anti-bacterial agents | AVENTIS PHARMA S.A. | 2007-12-27 | — | — | US | disclosed |
| US-7112592-B2 | topical bactericides and disinfectants for surgical instruments; staphylococci; coliform bacteria; 7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide; bridged bicyclic ureas or carbamates having bridgehead nitrogen | AVENTIS PHARMA S.A. (FR) | 2006-09-26 | — | — | US | disclosed |
| US-20060189652-A1 | New heterocyclic compounds, their preparation and their use as medicaments, in particular as anti-bacterial agents | AVENTIS PHARMA S.A. | 2006-08-24 | — | — | US | disclosed |
| US-20060046995-A1 | Heterocyclic compounds, their preparation and their use as medicaments, in particular as anti-bacterial agents | AVENTIS PHARMA S.A. | 2006-03-02 | — | — | US | disclosed |
| US-20050020572-A1 | Heterocyclic compounds as inhibitors of beta-lactamases | AVENTIS PHARMA S.A. (FR) | 2005-01-27 | — | — | US | disclosed |
| US-20030199541-A1 | Azabicyclic compounds, preparation thereof and use as medicines, in particular as antibacterial agents | ALLERGAN PHARMACEUTICALS INTERNATIONAL LIMITED (IE) | 2003-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110245254-A1 | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF BETA-LACTAMASES | BACE1, GAA, CEL | NPC1 723/4885RAB9A 517/4885GRIN2B 4490/4885 |
| US-20110213147-A1 | New heterocyclic compounds, their preparation and their use as medicaments, in particular as anti-bacterial agents | NISCH, DDC, SDHA | NPC1 2935/4885RAB9A 2294/4885GRIN2B 3353/4885 |
| US-20100048528-A1 | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF BETA-LACTAMASES | BACE1, GAA, CEL | NPC1 723/4885RAB9A 517/4885GRIN2B 4490/4885 |
| US-20070299108-A1 | New heterocyclic compounds, their preparation and their use as medicaments, in particular as anti-bacterial agents | NISCH, DDC, SDHA | NPC1 2935/4885RAB9A 2294/4885GRIN2B 3353/4885 |
| US-20060046995-A1 | Heterocyclic compounds, their preparation and their use as medicaments, in particular as anti-bacterial agents | NISCH, SDHB, SDHA | NPC1 2789/4885RAB9A 2639/4885GRIN2B 3975/4885 |
| US-20060189652-A1 | New heterocyclic compounds, their preparation and their use as medicaments, in particular as anti-bacterial agents | NISCH, DDC, SDHA | NPC1 2935/4885RAB9A 2294/4885GRIN2B 3353/4885 |
| US-20050020572-A1 | Heterocyclic compounds as inhibitors of beta-lactamases | BACE1, GAA, CEL | NPC1 723/4885RAB9A 517/4885GRIN2B 4490/4885 |
| US-20110021772-A1 | New heterocyclic compounds, their preparation and their use as medicaments, in particular as anti-bacterial agents | NISCH, DDC, SDHA | NPC1 2935/4885RAB9A 2294/4885GRIN2B 3353/4885 |
| US-20090215747-A1 | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF BETA-LACTAMASES | BACE1, GAA, CEL | NPC1 723/4885RAB9A 517/4885GRIN2B 4490/4885 |
| US-20030199541-A1 | Azabicyclic compounds, preparation thereof and use as medicines, in particular as antibacterial agents | AZI2, NISCH, DCTPP1 | NPC1 1728/4885RAB9A 1330/4885GRIN2B 2038/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.